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Hospital, Jilin University, Changchun, China, 3 Division of Rheumatology, School of Medicine, University of Colorado Denver, 
Aurora, CO, USA, 4 Nanomedicine Laboratory, Department of Pharmacy, Centre for Pharmaceutical Nanotechnology and 
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While having tremendous potential as therapeutic and imaging tools, the clinical use of 
engineered nanoparticles has been associated with serious safety concerns. Activation 
of the complement cascade and the release of proinflammatory factors C3a and C5a 
may contribute to infusion-related reactions, whereas opsonization with C3 fragments 
promotes rapid recognition and clearance of nanomaterials by mononuclear phago-
cytes. We used dextran-coated superparamagnetic iron oxide nanoparticles (SPIO), 
which are potent activators of the complement system, to study the role of nanoparticle 
surface chemistry in inciting complement in human serum. Using complement inhibitors 
and measuring levels of fluid phase markers (sC5b-9, C5a, and Bb), we found that the 
majority of human complement activation by SPIO is through the alternative pathways 
(AP). SPIO prepared with high dextran/iron ratio showed some complement activation 
via calcium-sensitive pathways, but the AP was responsible for the bulk of complement 
activation and amplification. Activation via the AP required properdin, the positive regu-
lator of the alternative C3bBb convertase. Modification of sugar alcohols of dextran with 
alkylating, acylating, or crosslinking agents did not overcome complement activation 
and C3 opsonization. These data demonstrate that human complement activation is 
independent of dextran modification of SPIO and suggest a crucial role of the AP in 
immune recognition of nano-assemblies in human serum.
Keywords: iron oxide nanoparticles, complement c3, complement system proteins, properdin, dextran, lectin 
pathway, alternative pathway of complement
inTrODUcTiOn
Complement system is a critical component of the innate immunity that comprises ~5% of globulins 
and is responsible for eliminating and destroying pathogens (1). Complement activation via classical, 
lectin, and alternative pathways (AP) converge to form highly reactive thioester C3b that covalently 
binds to hydroxyls and amines on foreign surfaces (2, 3) resulting in the formation of membrane 
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FigUre 1 | Preparation of sPiO nWs with different dextran/Fe 
ratios: the particles were prepared with different ratios of dextran 
to Fe salt. The size of the SPIO aggregates increases as the ratio used 
in the precipitation reaction decreases, from single crystal (9 g) to smaller 
aggregates of several crystals (6 g) to polycrystalline (5–20 crystals) 
nanoworms (3 g).
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pore complex C5b-9 and extremely potent anaphylatoxins C3a 
and C5a (4). Opsonization by C3b and its cleaved products 
(e.g., iC3b, C3d) triggers immune recognition by neutrophils, 
eosinophils, lymphocytes, monocytes, red blood cells, and mac-
rophages (5, 6). Complement activation is also believed to con-
tribute toward infusion-related reactions with clinically approved 
nanopharmaceuticals, such as Doxil (liposomal doxorubicin), 
Taxol (Cremophor-paclitaxel), and Sandimmune (Cremophor-
cyclosporine A).
Despite the fact that numerous reports demonstrated comple-
ment activation by nanoparticles, liposomes, and micelles (7–22), 
the pathways of complement activation as function of surface 
properties are still poorly understood. One of the examples is 
superparamagnetic iron oxide (SPIO) nanoparticle, which is 
widely used not only as a contrast agent in magnetic resonance 
imaging (MRI) but also in the development of theranostic 
nanomedicines and experimental hyperthermia treatments (23). 
Previously, others and we described the preparation of high 
contrast SPIO nanoworms (SPIO NWs) (24–28) that consist of 
multiple Fe3O4 crystals embedded in 20 kDa linear dextran. We 
further reported that dextran-coated SPIO NWs activate com-
plement in mouse serum via the lectin pathway, but in human 
serum complement activation is via lectin and APs (24–28). 
Furthermore, others (3, 29–31) have pointed out that dextran-
coated particles consume complement, where the projected 
surface polymer in brush conformation is less efficient in comple-
ment consumption than a side-on conformation. In addition, it 
has been reported that crosslinked dextran (Sephadex) enhances 
complement activation, and substitution of alcohol groups can 
partially prevent this effect (32–34). Despite these advances, the 
effect of carbohydrate modifications of dextran-coated SPIO on 
the efficiency of complement activation has not been investigated. 
This knowledge is not only very critical for SPIO nanoparticles, 
which are clinically useful nanomaterials, but also for surface 
engineering of other carbohydrate-coated materials. Indeed, 
several iron oxide-based clinical contrast agents, such as Feridex 
and Combidex, have induced adverse reactions in a large number 
of patients, presumably as a result of complement activation.
Here, we prepared SPIO using different dextran/Fe ratios and 
studied the pathway of complement activation by measuring 
generation of fluid phase markers. Our results point to the critical 
role of the AP in complement activation by SPIO regardless of the 
dextran/Fe ratio and the nanoparticle size. We then used SPIO 
NWs prepared with low dextran/Fe ratio to further understand 
the effect of modification of sugar hydroxyls with alkylating and 
crosslinking agents on C3 opsonization. The results suggest that 
modifications of dextran coat are not an effective strategy to 
mitigate AP activation by these nanoparticles in humans.
resUlTs
alternative Pathway is the Main activation 
Pathway by sPiO regardless of Dextran/
Fe ratio and Particle size
We synthesized SPIO nanoparticles by mixing 20  kDa dextran 
with FeCl2 and FeCl3 and precipitating nanoparticles with 
ammonia (35). For the precipitation reaction, we used different 
dextran/Fe ratios (low ratio: 3.0 g/133.4 mg; intermediate ratio: 
6.0  g/133.4  mg; high ratio: 9.0  g/133.4  mg). Hydrodynamic 
size measurements (Figure  1) showed that particles prepared 
at intermediate and high dextran/Fe ratios (6 and 9 g dextran, 
respectively) were much smaller than particles prepared at low 
dextran/Fe ratio (3 g dextran), apparently due to a more efficient 
coating of individual crystals with dextran and prevention of 
intercrystal aggregation. Transmission electron microscopy 
(TEM) images (Figure 1) showed that SPIO particles prepared 
with higher dextran/Fe ratio were rounded with few crystal-
line Fe3O4 cores (Figure  1, bottom schematic), whereas SPIO 
prepared with low dextran/Fe ratio (3  g) were predominantly 
polycrystalline worm-like structures (we term them SPIO 
nanoworms or SPIO NWs).
The human complement (Figure 2) is triggered by foreign 
surfaces via the formation of activated C3(H2O) (AP turnover) 
or via calcium-sensitive pathways (classical or lectin). This 
activation leads to the initially deposited C3b that associates 
with factor B to form the AP convertase C3bBb, which cleaves 
additional C3 molecules. In order to study the pathway of com-
plement activation, nanoparticles were added to human serum 
at Fe concentration of 0.2 mg/mL. Measurement of the soluble 
terminal complex marker sC5b-9 showed that all formulations 
triggered complement to the same extent, regardless of the 
size and dextran/Fe ratio (Figure  3A). Addition of calcium 
chelator 10 mM EGTA/2.5 mM Mg2+ [to inhibit operation of 
calcium-sensitive pathways (36)] dramatically decreased (by 
40%) complement activation by NWs prepared with high and 
intermediate dextran/Fe ratios, but not by NWs prepared with 
low dextran/Fe ratio (Figure  3A). These data suggest that at 
higher dextran/Fe ratios, both calcium-sensitive and the APs 
contribute to complement activation, whereas at low dextran/Fe 
ratio, the activation proceeds exclusively via the AP. In order 
to investigate the contribution of calcium-sensitive pathways 
in formation of the AP convertase (Figure  2), we measured 
generation of Bb in sera deficient in C2, which is the critical 
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FigUre 2 | schematic representation of the upstream part of the complement cascade: assembly of different pathways on the foreign surface leads 
to the formation of complement convertases and generation of c3b and fluid phase markers.
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FigUre 3 | Mechanisms of complement activation studied with fluid phase markers: formulations of sPiO nWs are described in Figure 1 (dextran/Fe 
ratios abbreviated as 3, 6, and 9 g) were incubated in human sera at 0.2 mg Fe/ml as described in section “Materials and Methods”. Zymosan 
(positive control) was at 0.2 mg/mL; (a) generation of soluble terminal membrane attack complex sC5b-9 in a healthy human serum; (B) generation of Bb as a 
marker of the AP activation in C2-depleted serum [the same serum source as in (a), where C2 was depleted immunochemically] and after addition of recombinant 
C2 (650 μg/mL) to C2-depleted serum; (c,D) effect of properdin antibody on AP activation and C5a generation, respectively. White bars: no inhibitor, gray bars: 
control isotype matched antibody, black bars: anti-P antibody. Non-parametric two sided t-test, n = 3 (two different human sera were used, and the results of a 
typical experiment are presented); *p < 0.05; **p < 0.01. None of the SPIO NWs generated sC5b and Bb in the presence of 10 mM EDTA (not shown).
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A B
C
FigUre 4 | effect of crosslinking of sPiO nWs on the complement activation as measured with fluid phase markers. (a) Scheme of crosslinking as 
described previously (35) leads to the formation of 3D crosslinked hydrogel on the particle surface; (B,c) generation of membrane attack complex and Bb, 
respectively, in human serum. Particle concentration was 0.4 mg/mL, zymosan concentration was 0.2 mg/mL. White bars: no inhibitor; black bars: EGTA/Mg2+; light 
dotted bars: control isotype matched antibody; dark dotted bars: anti-P antibody. The crosslinking of dextran did not block complement activation and did not 
change the pathway of activation (AP). Non-parametric two-sided t-test, n = 3; *p < 0.05; **p < 0.01 (two different human sera were used, and the results of a 
typical experiment are presented).
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factor for calcium-sensitive pathways. According to Figure 3B, 
SPIO NWs showed no decrease in Bb in the absence of C2, 
whereas 6 and 9 g SPIO showed a 25% decrease in Bb in the 
absence of C2. Bb levels were restored to normal levels when 
C2, at a physiological concentration (650 μg/mL), was added 
to the depleted serum. Collectively, these experiments confirm 
that calcium-sensitive pathways contribute to the complement 
activation by NWs with more polysaccharide content. In order 
to understand to what extent complement activation can pro-
ceed in the absence of the AP, we tested Bb and C5a formation 
in presence of anti-properdin (P) antibodies. The AP convertase 
is stabilized by P, being present in blood at ~20 μg/mL. For all 
formulations regardless of the dextran/Fe ratio, anti-P block-
ing antibody [a potent blocker of the AP (37)] inhibited AP 
convertase generation by over 80% (Figure 3C) and prevented 
C5a release by over 70% (Figure 3D), Collectively, these data 
suggest that despite contribution of the calcium-sensitive 
pathways to the initiation of complement and formation of 
the AP convertase by particles prepared at high dextran/Fe 
ratio, the AP still plays a predominant role on the propagation 
of complement and generation of fluid phase markers for all 
tested formulations.
surface Modifications of sPiO nWs 
Do not Decrease complement 
activation and c3 Opsonization
Because 3 g SPIO NWs show only a single pathway of complement 
activation, as opposed to 6 and 9 g SPIO that exhibit also calcium-
dependent activation, in the subsequent studies, we studied the 
effect of surface modifications of SPIO NWs on complement 
activation. SPIO NWs are highly efficient MRI contrast agents 
(35), and their opsonization by C3 leads to immune cell uptake 
(38), therefore, strategies to block complement activation would 
have a great value in the translation of these particles. Previously, 
we reported that crosslinking dextran coat of SPIO NWs with 
epichlorohydrin (resulting in CL-NWs, Figure  4A) blocked 
lectin pathway activation and C3 opsonization in mouse serum, 
but this procedure did not block C3 opsonization in sera from 
human subjects (35). In order to determine the pathway respon-
sible for complement activation of CL-NWs in human serum, we 
measured the fluid markers sC5b-9 and Bb (Figures 4B,C). SPIO 
NWs and CL-NWs caused comparable AP activation that was 
not inhibited by 10 mM EGTA/2.5 mM Mg2+. At the same time, 
anti-P antibody, but not control antibody, blocked over 90% of 
sC5b-9 and Bb release for both SPIO NWs and CL-NWs. These 
A B
C D
FigUre 5 | Modifications of hydroxyl groups of sPiO nWs and cl-nWs do not decrease complement c3 opsonization. (a) Alkylation and acylation of 
hydroxyls on SPIO NWs and CL-NWs; (B) modifications in (a) did not decrease or even increased C3 opsonization; (c) modification of CL-NW hydroxyls with 
acetyl, carboxymethyl, and sulfoethyl groups; (D) modifications in (c) did not significantly decrease C3 opsonization in human serum. Three different human sera 
were used in triplicates, and the results of a typical experiment are presented.
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results confirm that complement activation by CL-NWs proceeds 
almost exclusively via the AP.
The AP is triggered by the initial deposition of C3b on 
a foreign surface via highly reactive thioester group that 
covalently attaches to amines and hydroxyls (39). Both 
dextran and crosslinked dextran contain hydroxyls available 
for nucleophilic attack of the thioester bond and subsequent 
deposition of C3b (Figure  4A). Previous report suggested 
that substituting hydroxyl groups could reduce complement 
consumption by Sephadex (crosslinked dextran beads) (32). 
In order to test the hypothesis whether substitution of dextran 
hydroxyls by alkylating and acylating agents could block com-
plement activation, we modified hydroxyl groups of SPIO NWs 
and CL-NWs with an esterifying agent 2-(2-methoxyethoxy)
acetyl chloride or etherifying agent 2-methoxyethoxymethyl 
chloride (Figure 5A) and measured C3 opsonization in human 
serum. According to Figure 5B, while there was a significant 
deposition of C3 on SPIO NWs, modification of hydroxyl 
groups did not diminish C3 opsonization. Moreover, there 
was no decrease in C3 opsonization after crosslinking and after 
modification of CL-NW hydroxyls (Figures  5A,B). There is 
evidence in the literature that the presence of anionic groups 
on the polysaccharide surface can promote binding of serum 
factor H, which is a negative regulator of the AP (3, 34). 
However, modification of hydroxyl groups of CL-NWs with 
carboxymethyl, acyl, or ethyl sulfonic groups (Figure 5C) did 
not decrease the level of C3 opsonization in human serum 
(Figure  5D).
DiscUssiOn
Previous work has confirmed complement activation on a 
variety of carbohydrate-coated surfaces (29–31) as well as by 
crosslinked dextran beads [Sephadex (32)]. In this work, we 
determined the role of surface modification of dextran-coated 
iron oxides on the efficiency of complement activation in 
human sera. The fluid phase assays we employed are designed 
to dissect the role of the AP and calcium-sensitive pathways 
in the complement activation (7, 10, 40). Using these assays, 
we found that regardless of the ratio of dextran/Fe used in 
the preparation of nanoparticles, the complement activation 
predominantly proceeds via the AP, and with some minor 
contribution of the calcium-sensitive pathways for formula-
tions prepared with a higher ratio of dextran/Fe. LP is likely 
the predominant calcium-sensitive pathway activated by these 
formulations due to the presence of polysaccharide coating, 
but this would need to be determined in a separate study. In 
addition, we found that particles prepared with low dextran/
Fe ratio incite complement via only the AP.
Complement activity toward nanosurfaces is generally much 
higher in human sera than in sera from other species (41). 
The main reason for such activity is the continuous, but slow 
6Wang et al. Complement Activation by Iron Oxide Nanoparticles
Frontiers in Immunology | www.frontiersin.org October 2016 | Volume 7 | Article 418
activation of the AP due to tick-over, or formation of fluid phase 
AP convertase C3(H2O)Bb, the initial deposition of C3b on the 
foreign surface (42). Albeit activation of the AP could happen in 
the fluid phase, a foreign surface provides the scaffold for C3b 
and properdin binding, which enhances the assembly of the 
C3bBb convertase and complement amplification (43). Another 
mechanism of the AP convertase formation could be the direct 
binding of C3 to the surface (44). Therefore, we reasoned 
that the modification of nanoparticle hydroxyl groups could 
block the initial seeding of C3b and hence the AP activation. 
Previously, Labarre and colleagues showed that the blocking of 
alcohol groups (main groups that reacts with thioester of C3b) 
on Sephadex by carboxymethyl residues (32) prevented comple-
ment activation. In addition, the same group demonstrated 
that the presence of sulfate groups on a surface can mitigate 
complement activation by attracting factor H, the inhibitor of 
the AP convertase (33). Unlike these findings, we demonstrate 
that blocking hydroxyl groups for SPIO NWs and crosslinked 
CL-NWs with alkylating, crosslinking, and negatively charged 
groups did not decrease C3 opsonization of SPIO NWs in 
human sera. Based on the inability of dextran hydroxyl substitu-
tions to block C3 opsonization of SPIO NWs and CL-NWs, it is 
possible that other surface entities could promote the binding 
of C3, including non-specifically absorbed proteins, and we are 
currently investigating this possibility. The differences between 
the above mentioned results and our particles could be related to 
the differences in the surface nano-architecture, which promote 
different binding of complement activators and inhibitors, and 
needs to be investigated further.
In conclusion, our data establish the AP as the critical pathway 
for many SPIO formulations. In recent years, the AP has shown 
to be the essential pathway of complement activation in health 
and disease (45). Due to its key role, the AP represents a unique 
therapeutic target in many pathological conditions (46–48). For 
many drug delivery nanoplatforms, the AP has shown to be a 
critical pathway for complement activation (20, 21, 49), and it is 
likely that this list will only grow. The future research will focus 
on specific approaches to block the AP activation, for example, 
by using properdin-blocking antibodies (50) or natural serum 
complement inhibitors (51).
MaTerials anD MeThODs
Materials
Iron salts (ferrous and ferric chloride) and 20  kDa dextran 
(range 15–25  kDa) were from Sigma–Aldrich (St. Louis, MO, 
USA). Epichlorohydrin, anhydrous DMSO, 2-chloroethanesul-
fonic acid, chloroacetic acid, and acetic anhydride were from 
Sigma, 2-(2-methoxyethoxy)acetyl chloride and 2-methoxy-
ethoxymethyl chloride were from Alfa Aesar. Goat anti-human 
complement C3 polyclonal antibody (catalog No. 0855444) was 
purchased from MP Biomedicals (Solon, OH, USA). Anti-goat, 
IRDye 800CW-labeled, secondary antibodies were from LI-COR 
Biosciences (Lincoln, NE, USA). Copper grids (300 mesh) 
were purchased from Electron Microscopy Sciences (Hatfield, 
PA, USA). Sera from normal female subjects were collected by 
Equitech-Bio (Kerrville, TX, USA) according to the company’s 
Institutional Review Board Protocol. All blood products and 
complement proteins were kept aliquoted at −80°C.
synthesis and Modification of sPiO 
nanoworms
Nanoworms were synthesized using a one-pot Molday and 
MacKenzie (52) precipitation method as described by us previ-
ously (35). The main variation of the protocol was the ratio of 
dextran and iron salts in the reaction as described in Figure 1. 
The molar ratio between Fe2+ and Fe3+ was kept the same. After 
the synthesis, particles were dialyzed in double distilled water, 
filtered through a 0.45-μm filter (Millipore), and stored at 4°C. 
TEM imaging was conducted to visualize the iron oxide core 
using FEI Tecnai Spirit BioTwin electron microscope (Electron 
Microscopy Facility at the University of Colorado Boulder). Size 
and zeta potential measurements of NPs were determined using a 
Zetasizer Nano ZS (Malvern Instruments Ltd., Malvern, UK). The 
intensity weighted size distribution peak value was used to report 
hydrodynamic diameters of NWs.
For dextran shell crosslinking with epichlorohydrin, a two-
step procedure was used as described before (35). For modifica-
tion of dextran hydroxyls, SPIO NWs prepared at low dextran/
Fe ratio (3 g dextran per 133.4 mg Fe salts), or the corresponding 
crosslinked CL-NWs were washed by ultracentrifugation in 
anhydrous DMSO two times and resuspended in anhydrous 
DMSO at 5.0 mg/mL (Fe concentration) in a borosilicate glass 
vial in the presence of 1  mg/mL of 4-dimethylaminopyridine 
(DMAP). Then, 2 mg/mL of 2-(2-methoxyethoxy)acetyl chloride 
or 2 mg/mL of 2-methoxyethoxymethyl chloride were added to 
the nanoparticles under stirring. Nanoparticles were incubated 
under nitrogen atmosphere with stirring at 37°C overnight, 
washed 3× in DMSO, 2× in DDW by ultracentrifugation, and 
resuspended in PBS for complement measurement. For modifica-
tion with acetic anhydride, chloroacetic acid, or chloroethanesul-
fonic acid, CL-NWs were resuspended in DDW at 5 mg/mL (Fe 
concentration), stirred for 30 min in 2N NaOH solution, and then 
reacted with acetic anhydride (5% v/v), chloroacetic acid (5 mg/
mL), or chloroethanesulfonic acid (5 mg/mL) at 37°C overnight 
with stirring. The particles were washed by ultracentrifugation 
and resuspended in PBS.
complement activation studies
Details of human serum preparation, characterization, and 
functional assessment of complement pathways were described 
in detail elsewhere (7, 10, 20). Briefly, serum was prepared from 
freshly collected blood of two healthy volunteers according to pro-
cedure by Lachmann (53). C2 was immunochemically depleted 
from human serum, and the depleted serum was characterized as 
described elsewhere (7, 10). To measure complement activation 
in vitro, we determined NW-induced rise of serum complement 
activation products C4d, Bb, C5a, and sC5b-9 using respective 
Quidel (Quidel, San Diego, CA, USA) ELISA kits according to 
the manufacturer’s protocols. In all measurements, the volume of 
NW to normal or C2-depleted sera volume was 1:4. NW-mediated 
complement activation was further monitored after restoration 
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of C2 (650  μg/mL) in C2-depleted serum. Zymosan (0.2  mg/
mL) was used as a positive control for complement activation 
throughout. Each experiment was repeated three times with sera 
from two healthy individuals.
analysis of Binding of Proteins to Particles
For binding assay of complement C3 and properdin, 1  mg/
mL (Fe) SPIO NWs were incubated with fresh serum at 1:3 
volume ratio. At the end of incubation, particles were washed 
three times with 1× PBS by centrifugation at 100,000× g at 4°C 
in 2 mM Ca2+/Mg2+ supplemented PBS using Beckman Optima 
TLX ultracentrifuge. The pellets were resuspended in 20 μL PBS, 
and 2 μL aliquots were applied in triplicate onto a nitrocellulose 
membrane (Bio-Rad). The membranes were blocked using 5% 
(w/w) non-fat dry milk in PBS-T (1× PBS with 0.1% v/v Tween® 
20) for 1  h at room temperature, probed with corresponding 
primary antibodies for 1  h at room temperature, followed by 
washing the membranes three times with PBS-T, and finally 
1  h incubation with the corresponding IRDye 800CW-labeled 
secondary antibodies against the primary antibody species. The 
signal was visualized using an Odyssey infrared imager (Li-COR 
Biosciences, Lincoln, NE, USA). The integrated dot intensity 
in the scanned images was determined from 16-bit grayscale 
images using ImageJ software and plotted using Prism 6 software 
(GraphPad Software, Inc., La Jolla, CA, USA). Each experiment 
was repeated two times using sera from two individuals.
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